Diagnostic Substances: AMAG Pharmaceuticals (NASDAQ:AMAG), Atossa Genetics Inc (NASDAQ:ATOS), Palatin Technologies (NYSEMKT:PTN), Meridian Bioscience (NASDAQ:VIVO)

AMAG Pharmaceuticals (NASDAQ:AMAG) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a research report issued to clients and investors on Tuesday. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) net profit margin is -15.30% and weekly performance is -4.97%. On last trading day company shares ended up $19.68. Analysts mean target price for the company is $23.33. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) distance from 50-day simple moving average is 5.12%.

Atossa Genetics (Nasdaq: ATOS) announced that it has received international registration for its quality management system. The International Organization for Standardization, or “ISO,” is the world’s largest developer of international standards which are recognized globally for their stringent criteria. ISO 13485 and 9001 requirements are among the most comprehensive of the approximately 19,000 standards established by the organization and serve as the model for quality management systems. Atossa Genetics Inc (NASDAQ:ATOS) shares advanced 1.20% in last trading session and ended the day on $1.69. ATOS Gross Margin is 40.00% and its return on assets is -77.90%. Atossa Genetics Inc (NASDAQ:ATOS) quarterly performance is -1.74%.

Palatin Technologies (NYSE:PTN) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a report issued on Tuesday. Palatin Technologies, Inc. (NYSEMKT:PTN) shares moved up 0.91% in last trading session and was closed at $1.11, while trading in range of $1.08-$1.16. Palatin Technologies, Inc. (NYSEMKT:PTN) year to date performance is 52.05%.

Zacks upgraded shares of Meridian Bioscience (NASDAQ:VIVO)from an underperform rating to a neutral rating in a research note issued to investors on Tuesday. Meridian Bioscience, Inc. (NASDAQ:VIVO) ended the last trading day at $20.39. Company weekly volatility is calculated as 2.22% and price to cash ratio as 22.18. Meridian Bioscience, Inc. (NASDAQ:VIVO) showed a negative weekly performance of -0.54%.